Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2010 - 2016)

Anika Therapeutics (ANIK) has 7 years of Non-Current Deffered Revenue data on file, last reported at $48000.0 in Q4 2016.

• Non-Current Deffered Revenue for Q4 2016 came in at $48000.0, down 27.27% year-over-year; the trailing twelve-month figure through Dec 2016 was $48000.0 (down 27.27% YoY), and the FY2016 annual result was $48000.0, down 27.27% from the prior year.
• Non-Current Deffered Revenue declined to $48000.0 in Q4 2016 per ANIK's latest filing, from $59000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $4.3 million in Q1 2012 and troughed at $48000.0 in Q4 2016.
• A 5-year average of $1.1 million and a median of $79940.5 in 2015 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2014 and 2015: Non-Current Deffered Revenue tumbled 97.21% in 2014, then soared 30.74% in 2015.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $2.2 million in 2012, then declined by 4.54% to $2.1 million in 2013, then sank by 95.04% to $102000.0 in 2014, then slumped by 35.29% to $66000.0 in 2015, then retreated by 27.27% to $48000.0 in 2016.
• Business Quant data shows ANIK's Non-Current Deffered Revenue at $48000.0 in Q4 2016, $59000.0 in Q3 2016, and $56000.0 in Q2 2016.